+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Upadacitinib"

Crohn's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis - Product Thumbnail Image

Crohn's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis

  • Report
  • September 2022
  • 232 Pages
  • Global
From
Ulcerative Colitis Market Forecast - Epidemiology & Pipeline Analysis 2022-2027 - Product Thumbnail Image

Ulcerative Colitis Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

  • Report
  • August 2022
  • 222 Pages
  • Global
From
Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 133 Pages
  • Global
From
Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029

  • Report
  • January 2024
  • 143 Pages
  • Global
From
JAK Inhibitors Market - Product Thumbnail Image

JAK Inhibitors Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Anti-Inflammatory Drugs Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Route of Administration; By Distribution Channel; and By Region - Product Thumbnail Image

Anti-Inflammatory Drugs Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Route of Administration; By Distribution Channel; and By Region

  • Report
  • October 2023
  • 145 Pages
  • Global
From
JAK inhibitors - Competitive Landscape, 2023 - Product Thumbnail Image

JAK inhibitors - Competitive Landscape, 2023

  • Report
  • April 2023
  • 180 Pages
  • Global
From
RINVOQ Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

RINVOQ Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Ankylosing Spondylitis (AS) - Market Insights, Epidemiology, and Market Forecast - 2032 - Product Thumbnail Image

Ankylosing Spondylitis (AS) - Market Insights, Epidemiology, and Market Forecast - 2032

  • Report
  • February 2022
  • 210 Pages
  • Global
From
Crohn's Disease Therapeutics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Distribution Channel, and Geography - Product Thumbnail Image

Crohn's Disease Therapeutics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Distribution Channel, and Geography

  • Report
  • March 2024
  • 150 Pages
  • Global
From
Inflammatory bowel disease (IBD) Therapeutics Market- Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027) - Product Thumbnail Image

Inflammatory bowel disease (IBD) Therapeutics Market- Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

  • Report
  • August 2022
  • 110 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027 - Product Thumbnail Image

Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

  • Report
  • October 2021
  • 288 Pages
  • Global
From
Atopic Dermatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Thumbnail Image

Atopic Dermatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • March 2025
  • 84 Pages
  • Global
From
Rheumatoid Arthritis Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type - Product Thumbnail Image

Rheumatoid Arthritis Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • Report
  • February 2024
  • 91 Pages
  • Global
From
Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 145 Pages
  • Global
From
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 714 Pages
  • Global
From
Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 632 Pages
  • Global
From
Loading Indicator

Upadacitinib is a type of immune disorder drug used to treat a variety of conditions, including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. It is a Janus kinase (JAK) inhibitor, meaning it works by blocking the activity of certain enzymes that are involved in the body's inflammatory response. Upadacitinib is taken orally and is available in both tablet and capsule form. It is typically prescribed in combination with other medications, such as methotrexate or corticosteroids. Upadacitinib has been shown to be effective in reducing symptoms of rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. It has also been found to be safe and well-tolerated in clinical trials. Common side effects include nausea, diarrhea, and headache. Some companies in the Upadacitinib market include AbbVie, Pfizer, and Eli Lilly. Show Less Read more